According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
It’s similar in concept to Casgevy, an approved medicine from Vertex Pharmaceuticals, but uses a different ... Jacob Bell ...
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...
Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...
We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43 rd Annual J.P. Morgan Healthcare ...
Zacks.com on MSN9d
Vertex Secures FDA Approval for New Cystic Fibrosis Drug AlyftrekVertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people ...
Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback